Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales &Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar
Kelvin M. Jones, Balasubramanyam Karanam, Jacqueline Jones-Triche, Maninder Sandey, Henry J. Henderson, Rajeev S. Samant, Samuel Temesgen, Clayton Yates, Deepa Bedi
Jiyan Su, Dan Li, Qianjun Chen, Muxia Li, Lu Su, Ting Luo, Danling Liang, Guoxiao Lai, Ou Shuai, Chunwei Jiao, Qingping Wu, Yizhen Xie, Xinxin Zhou
Org. Biomol. Chem., 2018, Accepted Manuscript DOI: 10.1039/C8OB02668H, PaperYong qiang Zhu, Meng Lei, Huayun Feng, Enhe Bai, Hui Zhou, Jia Wang, Yan ru Qin, Hao yang Zhang, Xueyuan Wang, Zhaogang Liu, Ou Hai, Jia Liu A series of novel dipeptidyl boronic acid compounds were designed, synthesized and biologically investigated the inhibition of β5 subunit of 20S proteasome and several compounds showed high activities with the... The content of this RSS Feed (c) The Royal Society of Chemistry
Jun Wang, Zhen-Yu He, Yong Dong, Jia-Yuan Sun, Wen-Wen Zhang, San-Gang Wu
ConclusionrMBC incidence declined over time with decreased HER2-positive distant recurrence, a shift to more triple-negative BC and consistently poor distant disease survival.
This study aimed to examine the prevalence and trends of breast cancer-related risk factors and characteristics in premenopausal underweight Korean women according to birth year cohort.MethodsSocioeconomic and breast cancer-related risk factors were investigated in 13,415 premenopausal women using nationwide cross-sectional surveys performed between 2007 and 2015. Underweight was defined as body mass index
ConclusionsThis study suggests that the ER S118P variant does not affect risk for breast cancer or hormone therapy resistance. Germline screening and modification of treatments for patients harboring this variant are likely not warranted.
AbstractBackgroundOncotypeDX recurrence score (RS)® has been found to predict recurrence and disease-free survival in patients with node negative breast cancer. Whether RS is useful in guiding locoregional therapy decisions is unclear. We sought to evaluate the relationship between RS and lymph node burden.MethodsPatients with invasive breast cancer who underwent sentinel lymph node dissection from 2010 to 2015 were identified from a prospectively maintained database. Patients were excluded if they were clinically node positive or if they received neoadjuvant chemotherapy. RS was classified as low ( 30). The as...
AbstractBreast is one of the most common primary origins of secondary ovarian cancer. There are some factors that influence the incidence of ovarian metastases (OM), such as histological type of primary cancer. OM from breast cancers are frequently asymptomatic until the masses have grown to certain size, and the metastatic tumors are frequently manifested as bilateral, solid, small ovarian masses. On the other hand, patients with a history of breast cancer have an increased risk of developing primary ovarian cancer (POC) than the general population. To differentiate OM from POC is essential as the optimal treatments and p...
CONCLUSION: Bone pain is a common and sometimes severe symptom of bone metastases in advanced breast cancer and a common reason for initiating BTA treatment. Safety and efficacy were the main factors considered by physicians when selecting BTAs. Past Presentations: Data previously presented at the ISPOR 18th Annual European Congress, Milan, Italy; November 7-11, 2015 and at the Breast Cancer Symposium, San Francisco, CA, USA; September 25-27, 2015. PMID: 30550358 [PubMed - as supplied by publisher]